author-photo

A. Hauschild

University of Kiel

77

Papers

2792

Citations

Citation Trend

Filter By

Papers (54) Sort By

Journal Conference Others

Precise On-Board Navigation of LEO Satellites with GNSS Broadcast Ephemerides

2020
- A. Hauschild
- O. Montenbruck
Show All
- Source
- Cite
- Save
Citations (2)
1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (13)
1560PDMajor determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (17)
1251PAdverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
1241PImpact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (41)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (109)
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (52)